These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1354052)

  • 1. PET studies of dopamine receptors in relation to antipsychotic drug treatment.
    Farde L; Nordström AL; Halldin C; Wiesel FA; Sedvall G
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():468A-469A. PubMed ID: 1354052
    [No Abstract]   [Full Text] [Related]  

  • 2. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride.
    Farde L; Halldin C; Stone-Elander S; Sedvall G
    Psychopharmacology (Berl); 1987; 92(3):278-84. PubMed ID: 2957716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential of positron-emission tomography for pharmacokinetic and pharmacodynamic studies of neuroleptics.
    Farde L; Wiesel FA; Nilsson L; Sedvall G
    Psychopharmacol Ser; 1989; 7():32-9. PubMed ID: 2574454
    [No Abstract]   [Full Text] [Related]  

  • 4. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.
    Farde L; Nordström AL; Wiesel FA; Pauli S; Halldin C; Sedvall G
    Arch Gen Psychiatry; 1992 Jul; 49(7):538-44. PubMed ID: 1352677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central D1- and D2-receptor occupancy during antipsychotic drug treatment.
    Wiesel FA; Farde L; Nordström AL; Sedvall G
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):759-67. PubMed ID: 1981395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
    Florijn WJ; Tarazi FI; Creese I
    J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective D1- and D2-dopamine receptor blockade both induces akathisia in humans--a PET study with [11C]SCH 23390 and [11C]raclopride.
    Farde L
    Psychopharmacology (Berl); 1992; 107(1):23-9. PubMed ID: 1534178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity.
    McQuade RD; Duffy RA; Coffin VL; Barnett A
    Eur J Pharmacol; 1992 Apr; 215(1):29-34. PubMed ID: 1355442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects.
    Schlaepfer TE; Pearlson GD; Wong DF; Marenco S; Dannals RF
    Am J Psychiatry; 1997 Sep; 154(9):1209-13. PubMed ID: 9286178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.
    Seeman P; Guan HC; Niznik HB
    Synapse; 1989; 3(1):96-7. PubMed ID: 2521961
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological evaluation of SCH-12679: evidence for an in vivo antagonism of D1-dopamine receptors.
    Breese GR; Criswell HE; McQuade RD; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1990 Feb; 252(2):558-67. PubMed ID: 1968972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride.
    Seeman P; Niznik HB; Guan HC
    Arch Gen Psychiatry; 1990 Dec; 47(12):1170-2. PubMed ID: 2244801
    [No Abstract]   [Full Text] [Related]  

  • 13. A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients.
    Farde L; Suhara T; Nyberg S; Karlsson P; Nakashima Y; Hietala J; Halldin C
    Psychopharmacology (Berl); 1997 Oct; 133(4):396-404. PubMed ID: 9372541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET studies of neuroreceptors in schizophrenia. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Wong DF
    Neuropsychopharmacology; 1992 Aug; 7(1):69-72; discussion 73-5. PubMed ID: 1388023
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on "The current status of PET scanning with respect to schizophrenia".
    Seeman P
    Neuropsychopharmacology; 1992 Aug; 7(1):55-7; discussion 73-5. PubMed ID: 1388022
    [No Abstract]   [Full Text] [Related]  

  • 16. PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease.
    Rinne JO; Laihinen A; Någren K; Bergman J; Solin O; Haaparanta M; Ruotsalainen U; Rinne UK
    J Neurosci Res; 1990 Dec; 27(4):494-9. PubMed ID: 1981915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic modeling of [11C]raclopride: combined PET-microdialysis studies.
    Endres CJ; Kolachana BS; Saunders RC; Su T; Weinberger D; Breier A; Eckelman WC; Carson RE
    J Cereb Blood Flow Metab; 1997 Sep; 17(9):932-42. PubMed ID: 9307606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current status of PET scanning with respect to schizophrenia.
    Sedvall G
    Neuropsychopharmacology; 1992 Aug; 7(1):41-54. PubMed ID: 1388021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benzazepine, SCH 23390, inhibits 3H-NPA binding in mouse brain in vivo.
    Andersen PH; Nielsen EB
    Acta Pharmacol Toxicol (Copenh); 1986 Oct; 59(4):315-8. PubMed ID: 2948372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.